Retraction to "Physiology and pharmacology of the cardiovascular adrenergic system" by Lymperopoulos, A. [Front. Physiol. 2013; 4:240] doi: 10.3389/fphys.2013.00240;Physiology and pharmacology of the cardiovascular adrenergic system

Frontiers in Physiology

Volumn 4 SEP, Issue , 2013, Pages

  Lymperopoulos, Anastasios ^a  

^a NOVA SOUTHEASTERN UNIVERSITY   (United States)

Author keywords

Adrenal gland; Adrenergic nervous system; Adrenergic receptor; Cardiac myocyte; Catecholamine; Heart failure

Indexed keywords

ADENYLATE CYCLASE; ADRENALIN; ADRENERGIC RECEPTOR; ALPHA 1 ADRENERGIC RECEPTOR; ALPHA 1A ADRENERGIC RECEPTOR; ALPHA 1B ADRENERGIC RECEPTOR; ALPHA 1D ADRENERGIC RECEPTOR; ALPHA 2 ADRENERGIC RECEPTOR; ALPHA 2A ADRENERGIC RECEPTOR; ALPHA 2B ADRENERGIC RECEPTOR; ALPHA 2C ADRENERGIC RECEPTOR; BETA 1 ADRENERGIC RECEPTOR; BETA 2 ADRENERGIC RECEPTOR; BETA 3 ADRENERGIC RECEPTOR; BETA ADRENERGIC RECEPTOR; CYCLIC AMP; CYCLIC AMP DEPENDENT PROTEIN KINASE; G PROTEIN COUPLED RECEPTOR KINASE 2; GUANOSINE DIPHOSPHATE; GUANOSINE TRIPHOSPHATE; INHIBITORY GUANINE NUCLEOTIDE BINDING PROTEIN; NEUROTRANSMITTER; NITRIC OXIDE SYNTHASE; NORADRENALIN; NORADRENALIN TRANSPORTER; STIMULATORY GUANINE NUCLEOTIDE BINDING PROTEIN;

ADRENAL GLAND; ADRENERGIC ACTIVITY; ADRENERGIC NERVE; ADRENERGIC STIMULATION; ADRENERGIC SYSTEM; ARTICLE; CARDIOVASCULAR EFFECT; CARDIOVASCULAR SYSTEM; HEART FAILURE; HEART FUNCTION; HEART MUSCLE CELL; HEART MUSCLE CONTRACTILITY; HEART RATE; HUMAN; HYPERACTIVITY; NERVE ENDING; NONHUMAN; NORADRENALIN RELEASE; PATHOPHYSIOLOGY; PROTEIN EXPRESSION; RECEPTOR DOWN REGULATION; RECEPTOR UPREGULATION; SIGNAL TRANSDUCTION; STARLING LAW; TISSUE PERFUSION;

EID: 84884585457     PISSN: None     EISSN: 1664042X     Source Type: Journal    
DOI: 10.3389/fphys.2015.00379     Document Type: Erratum

References (66)

1. Aggarwal, A., Esler, M. D., Lambert, G. W., Hastings, J., Johnston, L., and Kaye, D. M. (2002). Norepinephrine turnover is increased in suprabulbar subcortical brain regions and is related to whole-body sympathetic activity in human heart failure. Circulation 105, 1031-1033. doi: 10.1161/hc0902.105724
2. Aggarwal, A., Esler, M. D., Socratous, F., and Kaye, D. M. (2001). Evidence for functional presynaptic alpha-2 adrenoceptors and their down-regulation in human heart failure. J. Am. Coll. Cardiol. 37, 1246-1251. doi: 10.1016/S0735-1097(01)01121-4
3. Armour, J. A. (2004). Cardiac neuronal hierarchy in health and disease. Am. J. Physiol. Regul. Integr. Comp. Physiol. 287, R262-R271.
4. Arriza, J. L., Dawson, T. M., Simerly, R. B., Martin, L. J., Caron, M. G., Snyder, S. H., et al. (1992). The G-protein-coupled receptor kinases betaARK1 and betaARK2 are widely distributed at synapses in rat brain. J. Neurosci. 12, 4045-4055.
5. Backs, J., Haunstetter, A., Gerber, S. H., Metz, J., Borst, M. M., Strasser, R. H., et al. (2001). The neuronal norepinephrine transporter in experimental heart failure: evidence for a post-transcriptional downregulation. J. Mol. Cell. Cardiol. 33, 461-472. doi: 10.1006/jmcc.2000.1319
6. Brede, M., Nagy, G., Philipp, M., Sorensen, J. B., Lohse, M. J., and Hein, L. (2003). Differential control of adrenal and sympathetic catecholamine release by alpha2-adrenoceptor subtypes. Mol. Endocrinol. 17, 1640-1646. doi: 10.1210/me.2003-0035
7. Brede, M., Wiesmann, F., Jahns, R., Hadamek, K., Arnolt, C., Neubauer, S., et al. (2002). Feedback inhibition of catecholamine release by two different alpha2-adrenoceptor subtypes prevents progression of heart failure. Circulation 106, 2491-2496. doi: 10.1161/01.CIR.0000036600.39600.66
8. Bristow, M. R., Ginsburg, R., Minobe, W., Cubicciotti, R., Sageman, W. S., Lurie, K., et al. (1982). Decreased catecholamine sensitivity and β-adrenegic receptor density in failing human hearts. N. Engl. J. Med. 307, 205-211. doi: 10.1056/NEJM198207223070401
9. Bristow, M. R., Ginsburg, R., Umans, V., Fowler, M., Minobe, W., Rasmussen, R., et al. (1986). β1-and β2-adrenergic-receptor subpopulations in nonfailing and failing human ventricular myocardium: coupling of both receptor subtypes to muscle contraction and selective β1-receptor down-regulation in heart failure. Circ. Res. 59, 297-309. doi: 10.1161/01.RES.59.3.297
10. Brodde, O. E. (1993). Beta-adrenoceptors in cardiac disease. Pharmacol. Ther. 60, 405-430. doi: 10.1016/0163-7258(93)90030-H
11. Brum, P. C., Kosek, J., Patterson, A., Bernstein, D., and Kobilka, B. (2002). Abnormal cardiac function associated with sympathetic nervous system hyperactivity in mice. Am. J. Physiol. Heart Circ. Physiol. 283, H1838-H1845.
12. Bylund, D. B., Eikenberg, D. C., Hieble, J. P., Langer, S. Z., Lefkowitz, R. J., Minneman, K. P., et al. (1994). International union of pharmacology nomenclature of adrenoceptors. Pharmacol. Rev. 46, 121-136.
13. Chesley, A., Lundberg, M. S., Asai, T., Xiao, R. P., Ohtani, S., Lakatta, E. G., et al. (2000). The β2-adrenergic receptor delivers an antiapoptotic signal to cardiac myocytes through Gi-dependent coupling to phosphatidylinositol 3-kinase. Circ. Res. 87, 1172-1179. doi: 10.1161/01.RES.87.12.1172
14. Colucci, W. S., Wright, R. F., and Braunwald, E. (1986). New positive inotropic agents in the treatment of congestive heart failure. Mechanisms of action and recent clinical developments. N. Engl. J. Med. 314, 290-299. doi: 10.1056/NEJM198601303140506
15. Communal, C., Singh, K., Sawyer, D. B., and Colucci, W. S. (1999). Opposing effects of β1-and β2-aadrenergic receptors on cardiac myocyte apoptosis: role of a pertussis toxin-sensitive G protein. Circulation 100, 2210-2212. doi: 10.1161/01.CIR.100.22.2210
16. Daaka, Y., Luttrell, L. M., and Lefkowitz, R. J. (1997). Switching of the coupling of the beta2-adrenergic receptor to different G proteins by protein kinase A. Nature 390, 88-91. doi: 10.1038/36362
17. Docherty, J. R. (2002). Age-related changes in adrenergic neuroeffector transmission. Auton. Neurosci. 96, 8-12. doi: 10.1016/S1566-0702(01)00375-7
18. Dorn, G. W. II., Tepe, N. M., Lorenz, J. N., Koch, W. J., and Liggett, S. B. (1999). Low- and high-level transgenic expression of β2-adrenergic receptors differentially affect cardiac hypertrophy and function in Gα q-overexpressing mice. Proc. Natl. Acad. Sci. U.S.A. 96, 6400-6405. doi: 10.1073/pnas.96.11.6400
19. Du, X. J., Gao, X. M., Kiriazis, H., Moore, X. L., Ming, Z., Su, Y., et al. (2006). Transgenic alpha1A-adrenergic activation limits post-infarct ventricular remodeling and dysfunction and improves survival. Cardiovasc. Res. 71, 735-743. doi: 10.1016/j.cardiores.2006.06.015
20. Dzau, V. J., Colucci, W. S., Hollenberg, N. K., and Williams, G. H. (1981). Relation of the renin-angiotensin-aldosterone system to clinical state in congestive heart failure. Circulation 63, 645-651. doi: 10.1161/01.CIR.63.3.645
21. Eaton, M. J., and Duplan, H. (2004). Useful cell lines derived from the adrenal medulla. Mol. Cell. Endocrinol. 228, 39-52. doi: 10.1016/j.mce.2003.02.001
22. Ferguson, S. S. (2001). Evolving concepts in G protein-coupled receptor endocytosis: the role in receptor desensitization and signaling. Pharmacol. Rev. 53, 1-24.
23. Gauthier, C., Leblais, V., Kobzik, L., Trochu, J. N., Khandoudi, N., Bril, A., et al. (1998). The negative inotropic effect of beta3-adrenoceptor stimulation is mediated by activation of a nitric oxide synthase pathway in human ventricle. J. Clin. Invest. 102, 1377-1384. doi: 10.1172/JCI2191
24. Hein, L., Altman, J. D., and Kobilka, B. K. (1999). Two functionally distinct alpha2-adrenergic receptors regulate sympathetic neurotransmission. Nature 402, 181-184. doi: 10.1038/46040
25. Hogg, K., and McMurray, J. (2005). Neurohumoral pathways in heart failure with preserved systolic function. Prog. Cardiovasc. Dis. 47, 357-366. doi: 10.1016/j.pcad.2005.02.001
26. Huang, Y., Wright, C. D., Merkwan, C. L., Baye, N. L., Liang, Q., Simpson, P. C., et al. (2007). An alpha1A-adrenergic extracellular signal-regulated kinase survival signaling pathway in cardiac myocytes. Circulation 115, 763-772. doi: 10.1161/CIRCULATIONAHA.106.664862
27. Kaye, D., and Esler, M. (2005). Sympathetic neuronal regulation of the heart in aging and heart failure. Cardiovasc. Res. 66, 256-264. doi: 10.1016/j.cardiores.2005.02.012
28. Knowlton, K. U., Michel, M. C., Itani, M., Shubeita, H. E., Ishihara, K., Brown, J. H., et al. (1993). The alpha 1A-adrenergic receptor subtype mediates biochemical, molecular, and morphologic features of cultured myocardial cell hypertrophy. J. Biol. Chem. 268, 15374-15380.
29. Lang, C. C., Stein, C. M., Nelson, R. A., He, H. B., Belas, F. J., Blair, I. A., et al. (1997). Sympathoinhibitory response to clonidine is blunted in patients with heart failure. Hypertension 30, 392-397. doi: 10.1161/01.HYP.30.3.392
30. Leineweber, K., Wangemann, T., Giessler, C., Bruck, H., Dhein, S., Kostelka, M., et al. (2002). Age-dependent changes of cardiac neuronal noradrenaline reuptake transporter (uptake1) in the human heart. J. Am. Coll. Cardiol. 40, 1459. doi: 10.1016/S0735-1097(02)02168-X
31. Liggett, S. B., Tepe, N. M., Lorenz, J. N., Canning, A. M., Jantz, T. D., Mitarai, S., et al. (2000). Early and delayed consequences of beta(2)-adrenergic receptor overexpression in mouse hearts: critical role for expression level. Circulation 101, 1707-1714. doi: 10.1161/01.CIR.101.14.1707
32. Lindley, T. E., Doobay, M., Sharma, R., and Davisson, R. (2004). Superoxide is involved in the central nervous system activation and sympathoexcitation of myocardial infarction induced heart failure. Circ. Res. 94, 402-409. doi: 10.1161/01.RES.0000112964.40701.93
33. Lohse, M. J., Engelhardt, S., and Eschenhagen, T. (2003). What is the role of beta-adrenergic signaling in heart failure? Circ. Res. 93, 896-906.
34. Lymperopoulos, A. (2012). Ischemic emergency? endothelial cells have their own "adrenaline shot" at hand. Hypertension 60, 12-14. doi: 10.1161/HYPERTENSIONAHA.112.197020
35. Lymperopoulos, A., and Bathgate, A. (2012). Pharmacogenomics of the heptahelical receptor regulators G-protein-coupled receptor kinases and arrestins: the known and the unknown. Pharmacogenomics 13, 323-341. doi: 10.2217/pgs.11.178
36. Lymperopoulos, A., Rengo, G., and Koch, W. J. (2007). Adrenal adrenoceptors in heart failure: fine-tuning cardiac stimulation. Trends Mol. Med. 13, 503-511.
37. Lymperopoulos, A., Rengo, G., and Koch, W. J. (2012). GRK2 inhibition in heart failure: something old, something new. Curr. Pharm. Des. 18, 186-191. doi: 10.2174/138161212799040510
38. Lymperopoulos, A., Rengo, G., Funakoshi, H., Eckhart, A. D., and Koch, W. J. (2007). Adrenal GRK2 upregulation mediates sympathetic overdrive in heart failure. Nat. Med. 13, 315-323. doi: 10.1038/nm1553
39. Lymperopoulos, A., Rengo, G., Gao, E., Ebert, S. N., Dorn, I. I. G. W., and Koch, W. J. (2010). Reduction of sympathetic activity via adrenal-targeted GRK2 gene deletion attenuates heart failure progression and improves cardiac function after myocardial infarction. J. Biol. Chem. 285, 16378-16386. doi: 10.1074/jbc. M109.077859
40. Lymperopoulos, A., Rengo, G., Zincarelli, C., Soltys, S., and Koch, W. J. (2008). Modulation of adrenal catecholamine secretion by in vivo gene transfer and manipulation of G protein-coupled receptor kinase-2 activity. Mol. Ther. 16, 302-307. doi: 10.1038/sj.mt.6300371
41. Malliani, A., Pagani, M., Pizzinelli, P., Furlan, R., and Guzzetti, S. (1983). Cardiovascular reflexes mediated by sympathetic afferent fibers. J. Auton. Nerv. Syst. 7, 295-301. doi: 10.1016/0165-1838(83)90082-6
42. Mann, D. L., and Bristow, M. R. (2005). Mechanisms and models in heart failure: the biomechanical model and beyond. Circulation 111, 2837-2849. doi: 10.1161/CIRCULATIONAHA.104.500546
43. Morris, M. J., Cox, H. S., Lambert, G. W., Kaye, D. M., Jennings, G. L., Meredith, I. T., et al. (1997). Region-specific neuropeptide Y overflows at rest and during sympathetic activation in humans. Hypertension 29, 137-143. doi: 10.1161/01.HYP.29.1.137
44. Moura, E., Afonso, J., Hein, L., and Vieira-Coelho, M. A. (2006). Alpha2-adrenoceptor subtypes involved in the regulation of catecholamine release from the adrenal medulla of mice. Br. J. Pharmacol. 149, 1049-1058. doi: 10.1038/sj.bjp.0706950
45. Mudd, J. O., and Kass, D. A. (2008). Tackling heart failure in the twenty-first century. Nature 451, 919-928. doi: 10.1038/nature06798
46. Nikolaev, V. O., Moshkov, A., Lyon, A. R., Miragoli, M., Novak, P., Paur, H., et al. (2010). Beta2-adrenergic receptor redistribution in heart failure changes cAMP compartmentation. Science 327, 1653-1657. doi: 10.1126/science.1185988
47. Penn, R. B., Pronin, A. N., and Benovic, J. L. (2000). Regulation of G protein-coupled receptor kinases. Trends Cardiovasc. Med. 10, 81-89. doi: 10.1016/S1050-1738(00)00053-0
48. Pepper, G. S., and Lee, R. W. (1999). Sympathetic activation in heart failure and its treatment with beta-blockade. Arch. Intern. Med. 159, 225-234. doi: 10.1001/archinte.159.3.225
49. Philipp, M., and Hein, L. (2004). Adrenergic receptor knockout mice: distinct functions of 9 receptor subtypes. Pharmacol. Ther. 101, 65-74. doi: 10.1016/j.pharmthera.2003.10.004
50. Philipp, M., Bred, M., and Hein, L. (2002). Physiological significance of alpha(2)-adrenergic receptor subtype diversity: one receptor is not enough. Am. J. Physiol. Regul. Integr. Comp. Physiol. 283, R287-R295.
51. Pierpont, G. L., DeMaster, E. G., Reynolds, S., Pederson, J., and Cohn, J. N. (1985). Ventricular myocardial catecholamines in primates. J. Lab. Clin. Med. 106, 205-210.
52. Regitz, V., Leuchs, B., Bossaller, C., Sehested, J., Rappolder, M., and Fleck, E. (1991). Myocardial catecholamine concentrations in dilated cardiomyopathy and heart failure of different origins. Eur. Heart J. 12(Suppl. D), 171-174.
53. Reiter, E., and Lefkowitz, R. J. (2006). GRKs and beta-arrestins: roles in receptor silencing, trafficking and signaling. Trends Endocrinol. Metab. 17, 159-165. doi: 10.1016/j.tem.2006.03.008
54. Rengo, G., Leosco, D., Zincarelli, C., Marchese, M., Corbi, G., Liccardo, D., et al. (2010). Adrenal GRK2 lowering is an underlying mechanism for the beneficial sympathetic effects of exercise training in heart failure. Am. J. Physiol. Heart Circ. Physiol. 298, H2032-H2038. doi: 10.1152/ajpheart.00702.2009
55. Rengo, G., Lymperopoulos, A., Leosco, D., and Koch, W. J. (2011). GRK2 as a novel gene therapy target in heart failure. J. Mol. Cell. Cardiol. 50, 785-792. doi: 10.1016/j.yjmcc.2010.08.014
56. Rengo, G., Lymperopoulos, A., Zincarelli, C., Femminella, G., Liccardo, D., Pagano, G., et al. (2012a). Blockade of β-adrenoceptors restores the GRK2-mediated adrenal α(2) -adrenoceptor-catecholamine production axis in heart failure. Br. J. Pharmacol. 166, 2430-2440. doi: 10.1111/j.1476-5381.2012.01972.x
57. Rengo, G., Perrone-Filardi, P., Femminella, G. D., Liccardo, D., Zincarelli, C., de Lucia, C., et al. (2012b). Targeting the β-adrenergic receptor system through gprotein- coupled receptor kinase 2: a new paradigm for therapy and prognostic evaluation in heart failure: from bench to bedside. Circ. Heart Fail. 5, 385-391. doi: 10.1161/CIRCHEARTFAILURE.112.966895
58. Rockman, H. A., Koch, W. J., and Lefkowitz, R. J. (2002). Seven-transmembrane-spanning receptors and heart function. Nature 415, 206-212. doi: 10.1038/415206a
59. Rozec, B., Erfanian, M., Laurent, K., Trochu, J. N., and Gauthier, C. (2009). Nebivolol, a vasodilating selective beta(1)-blocker, is a beta(3)-adrenoceptor agonist in the nonfailing transplanted human heart. J. Am. Coll. Cardiol. 53, 1532-1538. doi: 10.1016/j.jacc.2008.11.057
60. Shannon, R., and Chaudhry, M. (2006). Effect of alpha1-adrenergic receptors in cardiac pathophysiology. Am. Heart J. 152, 842-850. doi: 10.1016/j.ahj.2006.05.017
61. Skeberdis, V. A., Gendviliene, V., Zablockaite, D., Treinys, R., Macianskiene, R., Bogdelis, A., et al. (2008). Beta3-adrenergic receptor activation increases human atrial tissue contractility and stimulates the L-type Ca2+ current. J. Clin. Invest. 118, 3219-3227.
62. Triposkiadis, F., Karayannis, G., Giamouzis, G., Skoularigis, J., Louridas, G., and Butler, J. (2009). The sympathetic nervous system in heart failure physiology, pathophysiology, and clinical implications. J. Am. Coll. Cardiol. 54, 1747-1762. doi: 10.1016/j.jacc.2009.05.015
63. Wang, H., Huang, B. S., Ganten, D., and Leenen, F. H. H. (2004). Prevention of sympathetic and cardiac dysfunction after myocardial infarction in transgenic rats deficient in brain angiotensinogen. Circ. Res. 94, 843-849. doi: 10.1161/01.RES.0000120864.21172.5A
64. Woodcock, E. A., Du, X. J., Reichelt, M. E., and Graham, R. M. (2008). Cardiac alpha 1-adrenergic drive in pathological remodelling. Cardiovasc. Res. 77, 452-462. doi: 10.1093/cvr/cvm078
65. Zhu, W. Z., Zheng, M., Koch, W. J., Lefkowitz, R. J., Kobilka, B. K., and Xiao, R. P. (2001). Dual modulation of cell survival and cell death by β2-adrenergic signalling in adult mouse cardiomyocytes. Proc. Natl. Acad. Sci. U.S.A. 98, 1607-1612. doi: 10.1073/pnas.98.4.1607
66. Zipes, D. P. (2008). Heart-brain interactions in cardiac arrhythmias: role of the autonomic nervous system. Cleve. Clin. J. Med. 75, S94-S96. doi: 10.3949/ccjm.75.Suppl_2.S94